Hutchmed to Receive $10 Million Milestone Payment Through Takeda

MT NewswiresDec 13 04:59 ET

Express News | Reported Earlier, HUTCHMED to Receive $10M Payment From Takeda As FRUZAQLA Achieves First National Reimbursement In Europe For Metastatic Colorectal Cance

BenzingaDec 13 02:38 ET

Hutchmed (China) (00013.HK): Following the first inclusion of FRUZAQLA (fruquintinib) in the healthcare insurance in Europe, a milestone payment from Takeda will be received.

Gelonghui reports on December 13 that Hutchmed (China) (00013.HK) announced it will receive a $10 million milestone payment from its partner Takeda (TSE: 4502/NYSE: TAK). Takeda has received a recommendation in December 2024 for FRUZAQLA to be included in public medical coverage for patients with previously treated metastatic colorectal cancer in Spain, marking the first recommendation for public medical coverage obtained in Europe. Colorectal cancer is the second leading cause of cancer-related deaths in Europe. FRUZAQLA received approval from the European Commission in June 2024.

Gelonghui FinanceDec 12 19:04 ET

Express News | HUTCHMED to Receive Milestone Payment From Takeda Following First European Reimbursement for Fruzaqla® (Fruquintinib)

ReutersDec 12 19:00 ET

China Grants Hutchmed Breakthrough Designation for Non-Small Cell Lung Cancer Drug

MT NewswiresDec 12 05:33 ET

Reported Earlier, HUTCHMED's ORPATHYS and TAGRISSO Combo Gains Therapy Designation in China for Advanced Lung Cancer

BenzingaDec 12 02:15 ET